NCT03204721View on ClinicalTrials.gov

Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis

NACompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

June 21, 2017

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Graft-Versus-Host Disease
Interventions
OTHER

Extracorporeal photophoresis (ECP)

The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient

Trial Locations (1)

Unknown

Tobias Gedde-Dhl, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT03204721 - Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis | Biotech Hunter | Biotech Hunter